Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
👀 Copy Legendary Investors' Portfolios in One Click
Copy For Free
- Information
- Research
- Analysis & Opinion
Edison Group's Comment & Analysis.
Access a complete archive of all posts and research produced by Edison Group, including current material.
Access a complete archive of all posts and research produced by Edison Group, including current material.
Chimeric Therapeutics: Acquiring An Exciting New NK Cell Technology
By Edison Group - Dec 06, 2021
Chimeric Therapeutics (ASX:CHM) has announced that it has entered into an exclusive option agreement to license the clinically validated, off the shelf, robust, enhanced natural killer (CORE-NK) cell...
Newmont Corporation: Q321 Results In Line With Prior Expectations
By Edison Group - Nov 11, 2021
Newmont's (NYSE:NEM) Q321 results were closely in line with our prior forecasts (see Exhibits 1 and 2), albeit with relative outperformance from its Australian operations largely offsetting...
BluGlass: Transition To Direct-To-Market Components Model
By Edison Group - Oct 06, 2021
During FY21 BluGlass (ASX:BLG) continued the transition from an equipment sales and licensing business to a direct-to-market components operation focused on rapidly expanding opportunities in the...
Alkane Resources: Boda And Tomingley Continue To Deliver
By Edison Group - Sep 01, 2021
On 16 August, Alkane Resources (ASX:ALK) published the assay results of 10 more holes drilled at Boda. While our estimate of the overall mineralised inventory at Boda has changed little as a result of...